Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834035 · ClinicalTrials.gov registry record · Phase 1
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
A Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa, sponsored by M. Peter Marinkovich.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06834035: Recruiting Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa, sponsored by M. Peter Marinkovich.
NCT06834035 is a Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa that is actively recruiting participants, run by M. Peter Marinkovich. The registered enrollment target is 8 participants, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06834035, a Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa, is actively recruiting participants, sponsored by M. Peter Marinkovich.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Primary Outcome
Occurrence of adverse events and effects
Conditions Studied
Interventions
- BIOLOGICAL Immunoglobulin G
Study Locations (1)
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2026-03-06 |
| Phase | Phase 1 |
What NCT06834035 shows while recruiting
NCT06834035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (58% lower).
The record links to 4 conditions, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which Immunoglobulin G is the first listed.
NCT06834035 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06834035 about?
NCT06834035 is a clinical study titled "Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa". The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and H...
What is the current status of trial NCT06834035?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-08-04. Estimated completion is 2026-03-06.
What conditions does trial NCT06834035 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita.
What interventions are being tested in trial NCT06834035?
The interventions under investigation include: Immunoglobulin G (BIOLOGICAL).
Who is sponsoring clinical trial NCT06834035?
This trial is sponsored by M. Peter Marinkovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06834035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06834035's enrollment target sits among peer trials
8 10th of 10 the lowest of 10 other Epidermolysis Bullosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epidermolysis Bullosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
COMPLETED · Phase 1
-
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
COMPLETED · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
-
Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution
COMPLETED · Early Phase 1
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI